» Articles » PMID: 20048206

Effects of Right Ventricular Ejection Fraction on Outcomes in Chronic Systolic Heart Failure

Overview
Journal Circulation
Date 2010 Jan 6
PMID 20048206
Citations 121
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Studies of the effect of right ventricular ejection fraction (RVEF) on outcomes in heart failure (HF) are limited by small sample size and short follow-up.

Methods And Results: We examined the effect of baseline RVEF on outcomes in 2008 Beta-Blocker Evaluation of Survival Trial (BEST) participants with HF and left ventricular ejection fraction <or=35% during 24 months of mean follow-up. RVEF, estimated by gated-equilibrium radionuclide ventriculography, was used to categorize patients into 4 RVEF groups: >or=40% (n=733), 30% to 39% (n=531), 20% to 29% (n=473), and <20% (n=271). Unadjusted rates for all-cause mortality in patients with RVEF >or=40%, 30% to 39%, 20% to 29%, and <20% were 27%, 32%, 35%, and 47%, respectively. When compared with patients with RVEF >or=40%, unadjusted hazard ratios and 95% confidence intervals for all-cause mortality for those with RVEF 30% to 39%, 20% to 29%, and <20% were 1.19 (0.97 to 1.46; P=0.087), 1.45 (1.17 to 1.78; P=0.001), and 1.98 (1.59 to 2.47; P<0.0001), respectively. Respective multivariable-adjusted hazard ratios (95% confidence intervals) for all-cause mortality associated with RVEF 30% to 39%, 20% to 29%, and <20% were 1.07 (0.87 to 1.32; P=0.518), 1.12 (0.89 to 1.40; P=0.328), and 1.32 (1.02 to 1.71; P=0.034), respectively. Adjusted hazard ratios (95% confidence intervals) for other outcomes associated with RVEF <20% (compared with >or=40%) were as follows: cardiovascular mortality, 1.33 (1.01 to 1.76; P=0.041); HF mortality, 1.61 (1.03 to 2.52; P=0.037); sudden cardiac death, 1.29 (0.87 to 1.91; P=0.212); all-cause hospitalization, 1.21 (1.00 to 1.47; P=0.056); and HF hospitalization, 1.39 (1.10 to 1.77; P=0.007).

Conclusions: Baseline RVEF <20% is a significant independent predictor of mortality and HF hospitalization in systolic HF.

Citing Articles

Placement of an elastic, biohybrid patch in a model of right heart failure with pulmonary artery banding.

Hayashi Y, Kim S, Fujii T, Pedersen D, Ozeki T, Jiang H Front Bioeng Biotechnol. 2025; 12:1485740.

PMID: 39902173 PMC: 11788599. DOI: 10.3389/fbioe.2024.1485740.


Sacubitril/valsartan on right ventricular-pulmonary artery coupling and albumin-bilirubin score in heart failure in Chinese patients with reduced ejection fraction.

Shi Y, Gao C, Xu Y, Yuan F J Cardiothorac Surg. 2025; 20(1):72.

PMID: 39833911 PMC: 11749358. DOI: 10.1186/s13019-024-03224-6.


Right atrial strain measured by 2D speckle-tracking echocardiography is associated with poor cardiac outcomes in patients with heart failure.

Nagai T, Watanabe T, Wanezaki M, Kobayashi T, Edamura S, Sugai T Heart Vessels. 2024; .

PMID: 39545951 DOI: 10.1007/s00380-024-02485-4.


How Right is the Right Ventricle in Predicting Cardiac Mortality in Cardiac Failure: A 6-year Prospective Cohort Study.

Sljivic A, Kleut M, Celic V, Neskovic A, Nesic I, Gazibara T J Cardiovasc Echogr. 2024; 34(2):50-56.

PMID: 39086703 PMC: 11288295. DOI: 10.4103/jcecho.jcecho_13_24.


Incremental Value of Right Ventricular Outflow Tract Diameter in Risk Assessment of Chronic Heart Failure Patients with Implantable Cardioverter Defibrillators: Development of RVOTD-ICD Benefit Score in Real-World Setting.

Huang H, Deng Y, Cheng S, Yu Y, Liu X, Niu H Rev Cardiovasc Med. 2024; 24(9):269.

PMID: 39076385 PMC: 11270099. DOI: 10.31083/j.rcm2409269.


References
1.
Polak J, HOLMAN B, Wynne J, Colucci W . Right ventricular ejection fraction: an indicator of increased mortality in patients with congestive heart failure associated with coronary artery disease. J Am Coll Cardiol. 1983; 2(2):217-24. DOI: 10.1016/s0735-1097(83)80156-9. View

2.
Bogaard H, Abe K, Vonk Noordegraaf A, Voelkel N . The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest. 2009; 135(3):794-804. DOI: 10.1378/chest.08-0492. View

3.
. Design of the Beta-Blocker Evaluation Survival Trial (BEST). The BEST Steering Committee. Am J Cardiol. 1995; 75(17):1220-3. DOI: 10.1016/s0002-9149(99)80766-8. View

4.
Hesse B, Lindhardt T, Acampa W, Anagnostopoulos C, Ballinger J, Bax J . EANM/ESC guidelines for radionuclide imaging of cardiac function. Eur J Nucl Med Mol Imaging. 2008; 35(4):851-85. DOI: 10.1007/s00259-007-0694-9. View

5.
Haddad F, Doyle R, Murphy D, Hunt S . Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation. 2008; 117(13):1717-31. DOI: 10.1161/CIRCULATIONAHA.107.653584. View